<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77162">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01802645</url>
  </required_header>
  <id_info>
    <org_study_id>TUD-CELIM2-050</org_study_id>
    <secondary_id>2011-003288-31</secondary_id>
    <nct_id>NCT01802645</nct_id>
  </id_info>
  <brief_title>Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases</brief_title>
  <acronym>CELIM2</acronym>
  <official_title>Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized phase II trial to demonstrate efficacy of neoadjuvant treatment of patients with
      non-resectable liver metastases with:

        -  Cetuximab/FOLFOXIRI compared to cetuximab/FOLFIRI in patients with k-ras/b-raf wild
           type tumours and

        -  Bevacizumab/FOLFOXIRI compared to FOLFOXIRI in patients with k-ras mutant tumours with
           regard to response rates and rate of patients who had a R0 resection of all lesions and
           are disease free for at least 6 months (secondary aim).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with liver metastases from colorectal and without known extrahepatic metastases
      will be screened for this study. During screening, tumour blocks and blood samples will be
      sent for central diagnostic of k-ras/b-raf and UGT1A1 status. B-raf mutant patients are not
      treated within the trial.

      Patients receive chemotherapy according to the allocation and are re-evaluated for
      resectability every 8 weeks for a maximum of 6 months. Resectable patients will be resected
      and receive an adjuvant treatment to complete 12 cycles. In circumstances detailed in the
      protocol, a second resection is allowed within the study.

      Patients will be randomized using a web-based computer system that allows randomization if
      the key basic characteristics are entered.

      Patients with k-ras and b-raf wild-type tumours will be randomized to receive:

        -  Cetuximab/FOLFIRI or

        -  Cetuximab/FOLFOXIRI

      Patients with k-ras mutations will be randomized to receive:

        -  FOLFOXIRI or

        -  FOLFOXIRI/bevacizumab

      Chemotherapy doses are adjusted to the risk of toxicity in all treatment arms.

      Stratification will be performed according to:

        -  Number of metastases (&lt; 5 vs. ≥ 5 metastases)

        -  Primary tumour in situ

        -  Centre

      For dose reductions and conditions to continue please refer to the full protocol. All drugs
      are used within the label and approved doses.

      Patients are evaluated for response by the same imaging technique as at baseline every 8
      weeks. The findings will be discussed for resectability within two weeks after tumour
      assessment in a local multidisciplinary team.

      Technically resectable patients should be offered liver resection. The treatment will
      continue until liver resection or for a maximum of six months (12 cycles).

      After liver resection, an adjuvant treatment is recommended with the same schedule as
      preoperatively, for a maximum combined pre- and postoperative treatment of 12 cycles. If
      less than three postoperative cycles remain, no postoperative treatment will be started.

      After resection, patients will be followed up for 5 years after randomization. This includes

        -  imaging and clinical investigation every three months for the first 2 years, then every
           six months (patients without tumour progression / recurrence)

        -  survival status and surgical/medical treatment every three months for the first 2 years
           and then every six months (all patients).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of patients with partial or complete response according to modified RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of resected patients without early relaps</measure>
    <time_frame>6 months after resection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of patients who had a R0 resection of all lesions and are disease free for at least 6 months in the ITT population.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resection rate, defined as patients with microscopically complete (R0) resection (ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Resection rate</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of liver resection with macroscopically tumour free margins and/or RFA (all patients with R0 or R1 resection and/or complete RFA of all lesion, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression free survival</measure>
    <time_frame>up to 3 years after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression free survival (Medium, Kaplan-Meier-estimation, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease free survival after resection</measure>
    <time_frame>up to 3 years after resection</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease free survival after resection (Medium, Kaplan-Meier-estimation, resected patients)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 year after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall survival (Kaplan-Meier-estimation, ITT- population)</description>
  </other_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Toxicity according to NCI-CTC criteria v. 4.0 Perioperative toxicity according to Clavien</description>
  </other_outcome>
  <other_outcome>
    <measure>Pathological response</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pathological response in the resected tumour tissue</description>
  </other_outcome>
  <other_outcome>
    <measure>Molecular markers</measure>
    <time_frame>up to 1 year after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of molecular predictive markers for response (i.e. other mutations in EGFR signalling pathway, EGFR ligands) and toxicity</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks
*reduced in UGT1A1 7/7 patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>Cetuximab/FOLFIRI</arm_group_label>
    <arm_group_label>Cetuximab/FOLFOXIRI</arm_group_label>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_label>Bevacizumab/FOLFOXIRI</arm_group_label>
    <other_name>Leukovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-resectable, histologically confirmed, synchronous or metachronous colorectal
             liver metastases.

          2. Non-resectability will be documented by a local multidisciplinary tumour board with
             participation of a surgeon experienced in liver surgery. Patients can be enrolled if
             they

             a) are technically non-resectable (locally determined by a multidisciplinary team
             discussion based on remaining functional liver tissue after resection, i.e.

             i) involvement of both portal veins, all hepatic veins, portal vein of the liver lobe
             and hepatic veins draining the segments of the other liver lobe, or ii) other reasons
             for less than 30% remaining functional liver tissue after resection) and / or b) have
             ≥ 5 liver metastases and / or c) are regarded as non-resectable for other reasons
             (description necessary)

          3. Patients with simultaneous liver metastases are eligible,

               1. if the primary tumour was resected at least 1 month prior to chemotherapy or

               2. all of the following conditions apply:

             i) the primary tumour is clearly resectable, ii) no radiation therapy is planned,
             iii) liver resection is planned before resection of the primary or at the same
             operation as the resection of the primary, iv) no two-stage liver resection is
             planned, and v) all efforts were made to exclude additional distant metastases.

          4. WHO PS ≤ 1

          5. Written informed consent

          6. Adequate bone marrow function, liver function (neutrophils &gt; 1.5 x 109/l; platelets &gt;
             100 x 109/l; haemoglobin &gt; 5.0 mmol/l [8.0 g/dl]; bilirubin ≤ ULN or ≤ 1.5 x ULN and
             not increasing more than 25 % within the last 4 weeks; SGOT and SGPT &lt; 5 x UNL)

          7. Age ≥ 18 years

        Exclusion Criteria:

          1. Any evidence of extrahepatic metastases, distant lymph node metastases and primary
             tumour recurrence

          2. Patients with b-raf mutations

          3. Prior systemic antitumour therapy with anti- EGFR-, antiangiogenic drugs or with
             chemotherapy (except adjuvant chemotherapy for stage II / III with an interval of ≥ 6
             months or in combination with radiation as radio sensitizer)

          4. Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic
             interventions or venous port implantation) ≤ 4 weeks before study entry

          5. Renal insufficiency with serum creatinine ≥ 1.5 x UNL. If serum creatinine is between
             1.0 and 1.5 x UNL, the creatinine clearance according to the Cockroft-Gault formula
             should be ≥ 60 ml/min

          6. Hypertension with an arterial blood pressure &gt; 150/90 mmHg

          7. Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV, unstable angina pectoris, history of myocardial infarction within the last 12
             months, significant arrhythmias

          8. Known proteinuria &gt; 1 g/day (to be tested if proteinuria more than 1+ in the urinary
             dipstick analysis)

          9. Peripheral neuropathy &gt; CTC grade I

         10. Concurrent systemic immune therapy, chemotherapy, hormone therapy, or patients
             receiving immune suppressive treatment (i.e. for transplantation, severe
             rheumatologic disease)

         11. Participation in clinical trials with investigational agents within 30 days before
             start of the treatment in study

         12. Active treatment of

               1. peptic ulcers or bleeding erosive esophagitis / gastritis within 3 months before
                  study

               2. stroke, transient ischemic attack or symptomatic pulmonary embolism within 6
                  months before study

               3. deep vein thrombosis within 4 weeks before study

         13. Inflammatory bowel disease

         14. History of other malignancies, from which the patient is not 5 years disease free,
             with the exception of colorectal cancer, or adequately treated basal cell or squamous
             cell carcinoma of skin or in-situ cervical cancer within 5 years before study

         15. History of brain metastases

         16. History of severe psychiatric illness

         17. Active drug- or alcohol abuse

         18. Known hepatitis B or C or HIV infection

         19. Breast- feeding or pregnant women

         20. Lack of effective contraception (for male and female patients, during study until 6
             months after end of treatment)

         21. Known intolerance to one of the following drugs: cetuximab, bevacizumab, oxaliplatin,
             irinotecan, 5-FU, folinic acid
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Folprecht, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital &quot;Carl Gustav Carus&quot; Dresden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunnar Folprecht, PD Dr.</last_name>
    <phone>+49 351 458 4794</phone>
    <email>Gunnar.Folprecht@uniklinikum-dresden.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Schubert</last_name>
    <phone>+49 351 79 656 20</phone>
    <email>Olga.Schubert@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum der RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulf-Peter Neumann, Prof. Dr.</last_name>
      <phone>0241 8085660</phone>
      <email>chirurgie@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Ulf-Peter Neumann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Seehofer, PD Dr. med.</last_name>
      <phone>030/ 450 652062</phone>
      <email>daniel.seehofer@charite.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Seehofer, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Folprecht, PD Dr. med.</last_name>
      <phone>+49 351 458 4794</phone>
      <email>Gunnar.Folprecht@uniklinikum-dresden.de</email>
    </contact>
    <contact_backup>
      <last_name>Olga Schubert</last_name>
      <phone>+49 351 7965620</phone>
      <email>olga.schubert@uniklinikum-dresden.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gunnar Folprecht, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Torsten Liersch, PD Dr. med.</last_name>
      <phone>0551/ 398323</phone>
      <email>tliersch@chirurgie-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Torsten Liersch, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Arnold, Prof. Dr.</last_name>
      <phone>040/ 7410 55489</phone>
      <email>d.arnold@uke.de</email>
    </contact>
    <investigator>
      <last_name>Dirk Arnold, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Lordick, Pr.</last_name>
      <phone>+49 341 97 12560</phone>
      <email>Florian.Lordick@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Florian Lordick, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Möhler, PD Dr.</last_name>
      <phone>+49 6131 17 6863</phone>
      <email>markus.moehler@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Markus Möhler, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg GmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus-Henning Köhne, Prof. Dr.</last_name>
      <phone>+49 441 403-2610</phone>
      <email>onkologie@klinikum-oldenburg.de</email>
    </contact>
    <investigator>
      <last_name>Claus-Henning Köhne, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Kunzmann, PD Dr. med.</last_name>
      <phone>0931/20140746</phone>
      <email>kunzmann_v@medizin.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Volker Kunzmann, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>February 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant</keyword>
  <keyword>cetuximab</keyword>
  <keyword>irinotecan</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Resection</keyword>
  <keyword>colorectal liver metastases</keyword>
  <keyword>liver resection</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>k-ras</keyword>
  <keyword>non-resectable</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
